2013
DOI: 10.1111/dom.12115
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: AimThe efficacy and safety of insulin degludec (IDeg), a new basal insulin with an ultra-long duration of action, was compared to sitagliptin (Sita) in a 26-week, open-label trial.MethodsInsulin-naïve subjects with type 2 diabetes [n = 458, age: 56 years, diabetes duration: 7.7 years, glycosylated haemoglobin (HbA1c):8.9% (74 mmol/mol)] were randomized (1:1) to once-daily IDeg or Sita (100 mg orally) as add-on to stable treatment with 1 or 2 oral antidiabetic drugs (OADs).ResultsSuperiority of IDeg to Sita in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
27
1

Year Published

2013
2013
2017
2017

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 34 publications
(30 citation statements)
references
References 23 publications
2
27
1
Order By: Relevance
“…Nevertheless, the rate is in the same order of magnitude as the rates observed with concomitant administration of basal insulin and sulphonylureas . Importantly, this comparable risk of hypoglycaemia with IDegLira was achieved at a much lower end‐of‐trial HbA 1c compared with most previous trials of insulin initiation in Type 2 diabetes, including those combining basal insulin with sulphonylureas . There was no significant difference in the rate of nocturnal confirmed hypoglycaemia between treatment groups.…”
Section: Discussionmentioning
confidence: 64%
“…Nevertheless, the rate is in the same order of magnitude as the rates observed with concomitant administration of basal insulin and sulphonylureas . Importantly, this comparable risk of hypoglycaemia with IDegLira was achieved at a much lower end‐of‐trial HbA 1c compared with most previous trials of insulin initiation in Type 2 diabetes, including those combining basal insulin with sulphonylureas . There was no significant difference in the rate of nocturnal confirmed hypoglycaemia between treatment groups.…”
Section: Discussionmentioning
confidence: 64%
“…Six months after our formal search (November 2014), the results of two large cardiovascular RCTs (Trial Evaluating Cardiovascular Outcomes with Sitagliptin and ELIXA) became available. We incorporated data from these two studies, and our final analysis included 100 RCTs enrolling 54 758 and 48 175 patients in IBT and comparator groups, respectively, with 103 trial populations (27 Sitagliptin, 9 Vildagliptin, 11 Saxagliptin, 13 Linagliptin, 8 Alogliptin, 13 Exenatide, 7 Liraglutide, 6 Albiglutide, 3 Dulaglutide, and 6 Lixisenatide trials). (Characteristics of included trials are provided in the Supporting Information).…”
Section: Resultsmentioning
confidence: 99%
“…Similarly, though DIGAMI-2 trial[20] had three arms, it was chosen the insulin and non-insulin arms were clearly defined and outcomes compared between these two. Finally, 18 clinical trials [15,16,[19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] were selected for meta-analysis (Figure 1). …”
Section: Literature Search Resultsmentioning
confidence: 99%